0.32 USD
↗ 0.03 (9.83%)AT CLOSE (11:59 AM EDT)
Outlook Therapeutics, Inc. Common Stock
OTLKNASDAQ • USD
0.32
↗ 0.00 (0.66%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
0.32
↗ 0.00 (0.66%)
Market: CLOSED
Open?$0.29
High?$0.32
Low?$0.28
Prev. Close?$0.29
Volume?4.1M
Avg. Volume?5.0M
VWAP?$0.31
Rel. Volume?0.82x
Bid / Ask
Bid?$0.31 × 600
Ask?$0.32 × 6.5K
Spread?$0.00
Midpoint?$0.31
Valuation & Ratios
Market Cap?38.6M
Shares Out?104.6M
Float?83.0M
Float %?99.9%
P/E Ratio?N/A
P/B Ratio?-1.00
EPS?-$0.85
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?0.35Weak
Quick Ratio?0.28Weak
Cash Ratio?0.18Low
Debt/Equity?-0.95Low
ValuationFAIRLY VALUED
Score67/100
P/E?N/A▾
P/B?-1.00CHEAP▾
P/S?187.83HIGH▾
P/FCF?N/A▾
EV/EBITDA?-1.1CHEAP▾
EV/Sales?323.87HIGH▾
Returns & Efficiency
ROE?266.8%STRONG▾
ROA?-564.0%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$66.6M
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Employees
17
Market Cap
38.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2016-05-13
Address
111 S. WOOD AVENUE
ISELIN, NJ 08830
Phone: (609) 619-3990
ISELIN, NJ 08830
Phone: (609) 619-3990